2024 Q2 Form 10-Q Financial Statement
#000089626224000022 Filed on April 25, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| Revenue | $591.2M | $571.4M |
| YoY Change | 6.91% | 2.7% |
| Cost Of Revenue | $326.9M | $321.5M |
| YoY Change | 9.91% | 2.08% |
| Gross Profit | $264.3M | $249.9M |
| YoY Change | 3.43% | 3.47% |
| Gross Profit Margin | 44.7% | 43.73% |
| Selling, General & Admin | $195.8M | $193.3M |
| YoY Change | -8.09% | -0.64% |
| % of Gross Profit | 74.07% | 77.37% |
| Research & Development | ||
| YoY Change | ||
| % of Gross Profit | ||
| Depreciation & Amortization | $6.358M | $6.138M |
| YoY Change | 2.56% | 7.8% |
| % of Gross Profit | 2.41% | 2.46% |
| Operating Expenses | $200.1M | $197.6M |
| YoY Change | -8.07% | -0.71% |
| Operating Profit | $52.20M | $52.29M |
| YoY Change | 38.11% | 23.32% |
| Interest Expense | $7.895M | -$5.482M |
| YoY Change | 541.35% | -172.93% |
| % of Operating Profit | 15.12% | -10.48% |
| Other Income/Expense, Net | -$2.984M | $1.090M |
| YoY Change | -162.91% | -114.21% |
| Pretax Income | $49.23M | $27.23M |
| YoY Change | -179.11% | -21.56% |
| Income Tax | $16.66M | $12.63M |
| % Of Pretax Income | 33.84% | 46.4% |
| Net Earnings | $32.30M | $14.40M |
| YoY Change | -140.24% | -42.96% |
| Net Earnings / Revenue | 5.46% | 2.52% |
| Basic Earnings Per Share | $0.99 | $0.44 |
| Diluted Earnings Per Share | $0.98 | $0.44 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 32.68M shares | 32.67M shares |
| Diluted Shares Outstanding | 33.05M shares | 32.98M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $149.9M | $108.2M |
| YoY Change | 57.15% | 118.94% |
| Cash & Equivalents | $149.9M | $108.2M |
| Short-Term Investments | ||
| Other Short-Term Assets | $26.13M | $58.86M |
| YoY Change | -50.13% | 149.59% |
| Inventory | ||
| Prepaid Expenses | $15.51M | $20.33M |
| Receivables | $356.9M | $359.4M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $555.9M | $526.4M |
| YoY Change | 30.33% | 29.81% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $44.65M | $131.1M |
| YoY Change | -63.26% | 293.1% |
| Goodwill | $1.245B | $1.245B |
| YoY Change | 0.0% | 0.0% |
| Intangibles | $100.8M | $101.8M |
| YoY Change | -3.73% | 1.85% |
| Long-Term Investments | $68.00M | $67.00M |
| YoY Change | 3.19% | 13.75% |
| Other Assets | $86.61M | $18.86M |
| YoY Change | 355.98% | -75.9% |
| Total Long-Term Assets | $1.561B | $1.563B |
| YoY Change | 0.36% | 1.43% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $555.9M | $526.4M |
| Total Long-Term Assets | $1.561B | $1.563B |
| Total Assets | $2.117B | $2.090B |
| YoY Change | 6.81% | 7.34% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $26.63M | $36.25M |
| YoY Change | -30.94% | -9.42% |
| Accrued Expenses | $147.0M | $305.4M |
| YoY Change | -48.66% | 121.45% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $37.70M | $37.23M |
| YoY Change | 19.82% | 38.41% |
| Total Short-Term Liabilities | $480.0M | $484.9M |
| YoY Change | 3.8% | 37.33% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $351.4M | $356.1M |
| YoY Change | -5.0% | -4.59% |
| Other Long-Term Liabilities | $845.0K | $63.05M |
| YoY Change | -98.62% | 1218.72% |
| Total Long-Term Liabilities | $352.2M | $419.1M |
| YoY Change | -18.3% | 10.89% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $480.0M | $484.9M |
| Total Long-Term Liabilities | $352.2M | $419.1M |
| Total Liabilities | $938.5M | $1.002B |
| YoY Change | -3.81% | 23.12% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | $794.6M | $762.3M |
| YoY Change | 13.09% | -2.63% |
| Common Stock | $803.4M | $795.1M |
| YoY Change | 4.5% | 4.8% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | $472.8M | $469.2M |
| YoY Change | 1.75% | 1.46% |
| Treasury Stock Shares | ||
| Shareholders Equity | $1.125B | $1.088B |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $2.117B | $2.090B |
| YoY Change | 6.81% | 7.34% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $32.30M | $14.40M |
| YoY Change | -140.24% | -42.96% |
| Depreciation, Depletion And Amortization | $6.358M | $6.138M |
| YoY Change | 2.56% | 7.8% |
| Cash From Operating Activities | $52.31M | -$6.541M |
| YoY Change | -13.91% | -125.2% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $1.571M | $2.893M |
| YoY Change | -79.99% | 114.3% |
| Acquisitions | $0.00 | |
| YoY Change | -100.0% | |
| Other Investing Activities | $0.00 | -$175.0K |
| YoY Change | -100.0% | -100.37% |
| Cash From Investing Activities | -$1.571M | -$3.068M |
| YoY Change | -79.72% | -106.68% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | $8.941M | |
| YoY Change | -83.84% | |
| Cash From Financing Activities | -14.08M | -8.550M |
| YoY Change | 28.55% | -84.97% |
| NET CHANGE | ||
| Cash From Operating Activities | 52.31M | -6.541M |
| Cash From Investing Activities | -1.571M | -3.068M |
| Cash From Financing Activities | -14.08M | -8.550M |
| Net Change In Cash | 36.65M | -18.16M |
| YoY Change | -12.86% | -221.33% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $52.31M | -$6.541M |
| Capital Expenditures | $1.571M | $2.893M |
| Free Cash Flow | $50.73M | -$9.434M |
| YoY Change | -4.11% | -138.33% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
321537000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
315010000 | usd |
| CY2024Q1 | us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
127946000 | usd |
| CY2023Q1 | us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
126339000 | usd |
| CY2024Q1 | amed |
Non Cash Compensation Excluding Merger Related Expenses
NonCashCompensationExcludingMergerRelatedExpenses
|
7433000 | usd |
| CY2023Q1 | amed |
Non Cash Compensation Excluding Merger Related Expenses
NonCashCompensationExcludingMergerRelatedExpenses
|
3273000 | usd |
| CY2024Q1 | amed |
Merger Related Expenses
MergerRelatedExpenses
|
20667000 | usd |
| CY2023Q1 | amed |
Merger Related Expenses
MergerRelatedExpenses
|
720000 | usd |
| CY2024Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
4271000 | usd |
| CY2023Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
4443000 | usd |
| CY2024Q1 | us-gaap |
Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
|
57941000 | usd |
| CY2023Q1 | us-gaap |
Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
|
64225000 | usd |
| CY2024Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
539795000 | usd |
| CY2023Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
514010000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
31619000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
42379000 | usd |
| CY2024Q1 | us-gaap |
Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
|
1727000 | usd |
| CY2023Q1 | us-gaap |
Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
|
406000 | usd |
| CY2024Q1 | us-gaap |
Interest Expense
InterestExpense
|
8119000 | usd |
| CY2023Q1 | us-gaap |
Interest Expense
InterestExpense
|
7517000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
910000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
123000 | usd |
| CY2024Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1090000 | usd |
| CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-682000 | usd |
| CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-4392000 | usd |
| CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-7670000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
27227000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
34709000 | usd |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
12633000 | usd |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
9800000 | usd |
| CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
14594000 | usd |
| CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
24909000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
194000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-337000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
14400000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
25246000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.44 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.78 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
32670000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
32558000 | shares |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.44 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.77 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
32979000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
32643000 | shares |
| CY2023Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
1119783000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
0 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
7886000 | usd |
| CY2024Q1 | amed |
Surrendered Shares
SurrenderedShares
|
617000 | usd |
| CY2024Q1 | amed |
Contributions Attributable To Noncontrolling Interest
ContributionsAttributableToNoncontrollingInterest
|
1764000 | usd |
| CY2024Q1 | us-gaap |
Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
|
756000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
1142654000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
1106573000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
816000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
0 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3273000 | usd |
| CY2023Q1 | amed |
Surrendered Shares
SurrenderedShares
|
1308000 | usd |
| CY2023Q1 | us-gaap |
Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
|
-630000 | usd |
| CY2023Q1 | us-gaap |
Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
|
285000 | usd |
| CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
24909000 | usd |
| CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
14594000 | usd |
| CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
24909000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
6138000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
5694000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7886000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3273000 | usd |
| CY2024Q1 | amed |
Amortizationand Impairmentof Operating Lease Right Of Use Asset
AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
|
8566000 | usd |
| CY2023Q1 | amed |
Amortizationand Impairmentof Operating Lease Right Of Use Asset
AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
|
8622000 | usd |
| CY2024Q1 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-4000 | usd |
| CY2023Q1 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
70000 | usd |
| CY2024Q1 | us-gaap |
Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
|
0 | usd |
| CY2023Q1 | us-gaap |
Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
|
-2186000 | usd |
| CY2024Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
2594000 | usd |
| CY2023Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
2772000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
910000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
123000 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
248000 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
248000 | usd |
| CY2024Q1 | us-gaap |
Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
|
170000 | usd |
| CY2023Q1 | us-gaap |
Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
|
1787000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
46806000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
7476000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1696000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
4128000 | usd |
| CY2024Q1 | amed |
Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
|
-1042000 | usd |
| CY2023Q1 | amed |
Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
|
-918000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-155000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
111000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
8652000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-3457000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
3029000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
741000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-591000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-28000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-7532000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-7960000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6541000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
25961000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
|
21000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
|
19000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2670000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1350000 | usd |
| CY2024Q1 | us-gaap |
Payments To Develop Software
PaymentsToDevelopSoftware
|
223000 | usd |
| CY2023Q1 | us-gaap |
Payments To Develop Software
PaymentsToDevelopSoftware
|
210000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
|
196000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
|
0 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
|
0 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
|
47787000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
0 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
350000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-3068000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
45896000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
0 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
816000 | usd |
| CY2024Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
617000 | usd |
| CY2023Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
1308000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
|
1764000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
|
0 | usd |
| CY2024Q1 | amed |
Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
|
756000 | usd |
| CY2023Q1 | amed |
Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
|
285000 | usd |
| CY2024Q1 | us-gaap |
Payments To Minority Shareholders
PaymentsToMinorityShareholders
|
0 | usd |
| CY2023Q1 | us-gaap |
Payments To Minority Shareholders
PaymentsToMinorityShareholders
|
800000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Short Term Debt
ProceedsFromShortTermDebt
|
0 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Short Term Debt
ProceedsFromShortTermDebt
|
8000000 | usd |
| CY2024Q1 | us-gaap |
Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
|
0 | usd |
| CY2023Q1 | us-gaap |
Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
|
8000000 | usd |
| CY2024Q1 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
8941000 | usd |
| CY2023Q1 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
55313000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-8550000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-56890000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-18159000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
14967000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
138863000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
54133000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
120704000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
69100000 | usd |
| CY2024Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
8188000 | usd |
| CY2023Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
6654000 | usd |
| CY2024Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
828000 | usd |
| CY2023Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
352000 | usd |
| CY2024Q1 | amed |
Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
|
8574000 | usd |
| CY2023Q1 | amed |
Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
|
8878000 | usd |
| CY2024Q1 | amed |
Cash Paid For Finance Lease Liabilities
CashPaidForFinanceLeaseLiabilities
|
2236000 | usd |
| CY2023Q1 | amed |
Cash Paid For Finance Lease Liabilities
CashPaidForFinanceLeaseLiabilities
|
2457000 | usd |
| CY2024Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
7173000 | usd |
| CY2023Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
7083000 | usd |
| CY2024Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
4326000 | usd |
| CY2023Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
20790000 | usd |
| CY2024Q1 | amed |
Lessee Operatinglease Reductionsto Ro Uassetsresultingfromreductionstoleaseobligations
LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
|
168000 | usd |
| CY2023Q1 | amed |
Lessee Operatinglease Reductionsto Ro Uassetsresultingfromreductionstoleaseobligations
LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
|
141000 | usd |
| CY2024Q1 | amed |
Lessee Finance Lease Reductions To Rou Assets Resulting From Reductions To Finance Lease Obligations
LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations
|
496000 | usd |
| CY2023Q1 | amed |
Lessee Finance Lease Reductions To Rou Assets Resulting From Reductions To Finance Lease Obligations
LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations
|
369000 | usd |
| CY2024Q1 | us-gaap |
Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
|
37 | state |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div> | |
| CY2024Q1 | us-gaap |
Comparability Of Prior Year Financial Data
ComparabilityOfPriorYearFinancialData
|
<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to the prior period's financial statements in order to conform to the current year presentation. In the prior year, the Company combined merger-related expenses with other general and administrative expenses within the condensed consolidated income statement. Merger-related expenses are reflected as a separate line item in the current year. This reclassification had no effect on our previously reported net income.</span></div> | |
| CY2024Q1 | amed |
Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
|
1 | |
| CY2023Q1 | amed |
Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
|
1 | |
| CY2024Q1 | amed |
Net Service Revenue Episode Payment Rate Duration
NetServiceRevenueEpisodePaymentRateDuration
|
P60D | |
| CY2024Q1 | amed |
Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
|
P30D | |
| CY2024Q1 | amed |
Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
|
P30D | |
| CY2024Q1 | amed |
Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
|
P30D | |
| CY2024Q1 | amed |
Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
|
P30D | |
| CY2024Q1 | amed |
Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
|
P30D | |
| CY2024Q1 | amed |
Percentage Of Total Reimbursement Of Outlier Payment
PercentageOfTotalReimbursementOfOutlierPayment
|
0.10 | |
| CY2024Q1 | amed |
Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
|
P30D | |
| CY2024Q1 | amed |
Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
|
P30D | |
| CY2024Q1 | amed |
Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
|
0.97 | |
| CY2023Q1 | amed |
Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
|
0.97 | |
| CY2024Q1 | amed |
Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
|
0.97 | |
| CY2023Q1 | amed |
Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
|
0.97 | |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
108200000 | usd |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
126500000 | usd |
| CY2024Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
12500000 | usd |
| CY2023Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
12400000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
120700000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
138900000 | usd |
| CY2024Q1 | amed |
Percentage Of Patient Receivables Outstanding
PercentageOfPatientReceivablesOutstanding
|
0.10 | |
| CY2024Q1 | amed |
Accounts Receivable Portion Derived From Medicare
AccountsReceivablePortionDerivedFromMedicare
|
0.55 | |
| CY2023Q4 | amed |
Accounts Receivable Portion Derived From Medicare
AccountsReceivablePortionDerivedFromMedicare
|
0.69 | |
| CY2024Q1 | amed |
Historical Collection Rate From Medicare
HistoricalCollectionRateFromMedicare
|
0.99 | |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
323000 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
32670000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
32558000 | shares |
| CY2024Q1 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
10000 | shares |
| CY2023Q1 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
13000 | shares |
| CY2024Q1 | amed |
Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
|
299000 | shares |
| CY2023Q1 | amed |
Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
|
72000 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
32979000 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
32643000 | shares |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
388000 | shares |
| CY2024Q1 | amed |
Minimum Percent Ownership For Controlling Interest Percent
MinimumPercentOwnershipForControllingInterestPercent
|
0.50 | |
| CY2024Q1 | amed |
Maximum Percent Ownership For Equity Method Percent
MaximumPercentOwnershipForEquityMethodPercent
|
0.50 | |
| CY2024Q1 | us-gaap |
Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
|
47000000 | usd |
| CY2023Q4 | us-gaap |
Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
|
46100000 | usd |
| CY2024Q1 | amed |
Maximum Percent Ownership For Cost Method Percent
MaximumPercentOwnershipForCostMethodPercent
|
0.20 | |
| CY2024Q1 | us-gaap |
Investment Owned At Cost
InvestmentOwnedAtCost
|
20000000 | usd |
| CY2023Q4 | us-gaap |
Investment Owned At Cost
InvestmentOwnedAtCost
|
20000000 | usd |
| CY2024Q1 | amed |
Termination Fee Payable
TerminationFeePayable
|
106000000 | usd |
| CY2024Q1 | amed |
Termination Fee Payable
TerminationFeePayable
|
106000000 | usd |
| CY2023 | amed |
Closing Payment Adjustment Paid By Buyer
ClosingPaymentAdjustmentPaidByBuyer
|
100000 | usd |
| CY2024Q1 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
395600000 | usd |
| CY2023Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
400800000 | usd |
| CY2024Q1 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
2300000 | usd |
| CY2023Q4 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
2600000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
393300000 | usd |
| CY2023Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
398200000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
37200000 | usd |
| CY2023Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
36300000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
356100000 | usd |
| CY2023Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
361900000 | usd |
| CY2024Q1 | amed |
Merger Related Expenses
MergerRelatedExpenses
|
20700000 | usd |
| CY2024Q1 | amed |
Non Deductible Expense
NonDeductibleExpense
|
17000000 | usd |
| CY2024Q1 | amed |
Health Insurance Retention Limit
HealthInsuranceRetentionLimit
|
1500000 | usd |
| CY2024Q1 | amed |
Workers Compensation Insurance Retention Limit
WorkersCompensationInsuranceRetentionLimit
|
2000000 | usd |
| CY2024Q1 | amed |
Professional Liability Insurance Retention Limit
ProfessionalLiabilityInsuranceRetentionLimit
|
300000 | usd |
| CY2024Q1 | amed |
Fleet Insurance Exposure Limit
FleetInsuranceExposureLimit
|
500000 | usd |
| CY2024Q1 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
3 | segments |
| CY2024Q1 | us-gaap |
Revenues
Revenues
|
571400000 | usd |
| CY2024Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
321500000 | usd |
| CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
214000000.0 | usd |
| CY2024Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
4300000 | usd |
| CY2024Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
539800000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
31600000 | usd |
| CY2023Q1 | us-gaap |
Revenues
Revenues
|
556400000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
315000000.0 | usd |
| CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
194600000 | usd |
| CY2023Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
4400000 | usd |
| CY2023Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
514000000.0 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
42400000 | usd |
| CY2024Q1 | amed |
Merger Related Expenses
MergerRelatedExpenses
|
20700000 | usd |
| CY2023Q1 | amed |
Merger Related Expenses
MergerRelatedExpenses
|
700000 | usd |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false |
